Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 5/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.63 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163710 | 1.00 | AOC3 (1.00) | AOC3TAAR1TRPA1RIPK1NPC1 | |
| Hydrochloric Acid SCHEMBL11531581 | 0.98 | AOC3 (0.96) | AOC3TAAR1TRPA1RIPK1NPC1 | |
| SCHEMBL18459579 | 0.82 | AOC3 (0.69) | AOC3TAAR1GRIA4 | |
| SCHEMBL11046082 | 0.81 | TAAR1 (0.68) | AOC3TAAR1TRPA1RIPK1NPC1 | |
| SCHEMBL8720305 | 0.80 | AOC3 (0.67) | AOC3TAAR1GRIA4 | |
| SCHEMBL23783575 | 0.79 | TAAR1 (0.95) | AOC3TAAR1TRPA1RIPK1NPC1 | |
| Phenpromethamine SCHEMBL3958676 | 0.79 | TAAR1 (0.95) | AOC3TAAR1TRPA1RIPK1NPC1 | |
| Phenpromethamine SCHEMBL4917327 | 0.79 | TAAR1 (0.95) | AOC3TAAR1TRPA1RIPK1NPC1 | |
| Phenpromethamine SCHEMBL681384 | 0.79 | TAAR1 (0.95) | AOC3TAAR1TRPA1RIPK1NPC1 | |
| SCHEMBL11106041 | 0.78 | AOC3 (0.64) | AOC3TAAR1TRPA1RIPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004311-A1 | OPTICALLY PURE APOGOSSYPOL DERIVATIVE AS PAN-ACTIVE INHIBITOR OF ANTI-APOPTOTIC B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-01-05 | — | — | US | claimed |
| US-20120004311-A1 | OPTICALLY PURE APOGOSSYPOL DERIVATIVE AS PAN-ACTIVE INHIBITOR OF ANTI-APOPTOTIC B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004311-A1 | OPTICALLY PURE APOGOSSYPOL DERIVATIVE AS PAN-ACTIVE INHIBITOR OF ANTI-APOPTOTIC B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) | BCL3, BCL9, BCL2 | AOC3 1873/4885TAAR1 4637/4885TRPA1 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.